COVID-19 — and the mandate for social distancing to curb its spread — has meant rethinking how nearly 400 Vanderbilt University School of Medicine students will master the clinical and didactic skills they need to stay on course.

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.

In light of the need to prioritize our unified response to COVID-19, StrategyShare2020, originally scheduled for June 24, is being postponed until further notice.

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.

Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center.

Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.